Navigation path

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Indonesia
  Ireland
  Israel
  Italy
  Jamaica
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Mozambique
  Namibia
  Netherlands
  New Zealand
  Nigeria
  Norway
  Panama
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sri Lanka
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States
  Vietnam

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport


   Countries

Last Update: 28-05-2014  
Related category(ies):
Innovation  |  Information society  |  Health & life sciences  |  Industrial research  |  Nanotechnology

 

Countries involved in the project described in the article:
Belgium  |  France  |  Greece  |  Israel  |  Italy  |  Netherlands  |  Slovakia  |  Spain  |  United Kingdom
Add to PDF "basket"

Targeting cancerous tumours with precision

EU-funded researchers have developed novel technology for treating cancer patients that could deliver drugs exactly where they are needed in the human body. The potential breakthrough, which combines diagnosis and treatment, could significantly boost the effectiveness of the drugs currently used against cancer - giving patients a better chance of surviving.

Illustration of human cells

© freshidea fotolia

Cancer is second to cardiovascular disease as the leading cause of death in Europe. Conventional chemotherapy treatment for cancer patients relies on highly toxic drugs, mostly taken intravenously. Taken this way, these drugs can destroy both healthy and cancerous cells, causing harmful side-effects and other complications.

The EU-funded Nanother project used the science of nanotechnology as an alternate way of deliver these drugs more effectively, potentially boosting the benefits and reducing side-effects. Nanotechnology is the manipulation of materials at the nano scale – between 1 to 100 nanometres, with one nanometre equal to a billionth of a metre.

The project team, which completed its work in August 2012, selected and developed a number of promising particles at the nano size designed to seek out tumours and carry drugs directly to them. Using these so-called nanocarriers, medicines could be delivered far more precisely than chemotherapy treatments, in just the right amounts.

Along with developing nanoparticles as tiny tumour detectors and as drug carriers, the team also developed software to support the analysis of tumours and as a possible aid for diagnosis and therapy, says Dr Pedro Heredia of Fundación Gaiker, Nanother’s coordinator.

Seek and destroy

The team’s work has helped develop an approach to using nanoparticles, both to detect cancerous cells, and to destroy them, he adds. This approach points the way forward to creating and adapting suitable nanoparticles for particular types of cancerous tumours.

Patients would then be able to receive treatment that is best for their specific type of cancer. Since the treatment is targeted, patients would avoid being subjected to higher and thus potentially more harmful doses of drugs to ensure that sufficient quantities reach the cancerous cells.

The team has also identified nanoparticles that once injected into an area near a potential tumour, latch on to the targeted cells, generating crucial input for doctors to make decisions about the most effective treatment.

The ability to diagnose cancer at a very early stage, improves a patient’s chances of receiving successful treatment, says Dr Heredia.

Combining therapy and diagnostics

The project team included partners from the biomedical sector and from physical sciences and engineering collaborating across the traditional boundaries of their fields. The team’s research also benefited from the involvement of both businesses and academic organisations.

Industrial partners, says Dr Heredia, are highly market-oriented, whereas academia concentrates more on understanding things.

“Combining these two approaches added value to the project as we reached a consensus in the middle, doing good science, but focusing on the market,” he notes.

Dr Heredia says that more work is needed to refine the technology, adapt it for specific applications and prepare the proposed products for trials.

“Overall, if everything is OK, I would say no less than 10 years to market,” he says.

He adds: “In principle, the ideal situation would be to continue with the nanocarriers that have yielded good results and try to get onboard companies willing to further explore the business opportunities that may arise. We are in the process of searching for possible companies to exploit the research.”

 

Project details

  • Project acronym: NANOTHER
  • Participants:Spain (Coordinator), Italy, Israel, Netherlands, France, Belgium, Greece, UK, Slovakia
  • Project FP7 213631
  • Total costs: € 11 556 307
  • EU contribution: € 8 408 483
  • Duration: September 2008 - August 2012

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project web site
Project information on CORDIS






  Top   Research Information Center